Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
26.74
-2.78 (-9.42%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Avidity Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Net Income
-322.3-212.22-174-118.01-44.36
Upgrade
Depreciation & Amortization
2.782.11.390.640.37
Upgrade
Loss (Gain) From Sale of Investments
-21.45-11.27-0.620.180.01
Upgrade
Stock-Based Compensation
51.3638.2227.1417.064.31
Upgrade
Other Operating Activities
3.32.982.750.680.21
Upgrade
Change in Accounts Payable
35.181.7718.326.045.75
Upgrade
Change in Unearned Revenue
-10.3262.99-5.12-4.44-3.1
Upgrade
Change in Other Net Operating Assets
-39.43-3.63-6.133.04-0.32
Upgrade
Operating Cash Flow
-300.87-119.06-136.27-94.81-37.12
Upgrade
Capital Expenditures
-7.07-4.23-2.82-3.74-1.09
Upgrade
Investment in Securities
-847.14-125.84-187.13-78.78-6.69
Upgrade
Investing Cash Flow
-854.2-130.07-189.96-82.52-7.79
Upgrade
Long-Term Debt Repaid
-----4.68
Upgrade
Net Debt Issued (Repaid)
-----4.68
Upgrade
Issuance of Common Stock
1,05193.86346.17176.32274.52
Upgrade
Other Financing Activities
141.4----
Upgrade
Financing Cash Flow
1,19293.86346.17176.32272.04
Upgrade
Net Cash Flow
37.29-155.2719.95-1.01227.14
Upgrade
Free Cash Flow
-307.94-123.29-139.09-98.55-38.21
Upgrade
Free Cash Flow Margin
-2825.88%-1289.66%-1507.92%-1056.76%-562.97%
Upgrade
Free Cash Flow Per Share
-2.76-1.69-2.67-2.38-1.76
Upgrade
Cash Interest Paid
----0.57
Upgrade
Levered Free Cash Flow
-197.47-86.66-71.82-48.59-19.53
Upgrade
Unlevered Free Cash Flow
-197.47-86.66-71.82-48.59-19.4
Upgrade
Change in Net Working Capital
7.7-24.5-14.3-11.24-4.69
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q